Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations?

J Assist Reprod Genet. 2020 May 11;:

Authors: Nahata L, Woodruff TK, Quinn GP, Meacham LR, Chen D, Appiah LC, Finlayson C, Orwig KE, Laronda MM, Rowell EE, Anazodo A, Frias O, Rios JS, Whiteside S, Gomez-Lobo V, Dwiggins M, Childress KJ, Hoefgen HR, Levine JM, Jayasinghe Y, Moravek M

PMID: 32390071 [PubMed - as supplied by publisher]

Barriers and Opportunities of Oncofertility Practice in Nine Developing Countries and the Emerging Oncofertility Professional Engagement Network.

JCO Glob Oncol. 2020;6:

Authors: Salama M, Ataman-Millhouse L, Sobral F, Terrado G, Scarella A, Bourlon MT, Adiga SK, Udupa KS, Mahajan N, Patil M, Venter C, Demetriou G, Quintana R, Rodriguez G, Quintana T, Viale L, Bonilla YAR, Noguera JAR, Velásquez JCV, Pineda JID, Aldecoa MDC, Javed M, Al Sufyan H, Daniels N, Ogunmokun AA, Woodruff TK

Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe.

JCO Glob Oncol. 2020;6:

Engineered reproductive tissues.

Nat Biomed Eng. 2020 Apr 06;:

Authors: Gargus ES, Rogers HB, McKinnon KE, Edmonds ME, Woodruff TK

Abstract

Engineered male and female biomimetic reproductive tissues are being developed as autonomous in vitro units or as integrated multi-organ in vitro systems to support germ cell and embryo function, and to display characteristic endocrine phenotypic patterns, such as the 28-day human ovulatory cycle. In this Review, we summarize how engineered reproductive tissues facilitate research in reproductive biology, and overview strategies for making engineered reproductive tissues that might eventually allow the restoration of reproductive capacity in patients.

PMID: 32251392 [PubMed - as supplied by publisher]